Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Depreciation & Amortization (CF) (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Depreciation & Amortization (CF) data on record, last reported at $85000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 27.35% year-over-year to $85000.0; the TTM value through Dec 2025 reached $323000.0, up 7.67%, while the annual FY2025 figure was $323000.0, 7.67% up from the prior year.
  • Depreciation & Amortization (CF) reached $85000.0 in Q4 2025 per CTNM's latest filing, up from $81000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $117000.0 in Q4 2024 and bottomed at $42000.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $68583.3, with a median of $67500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 178.57% in 2024, then decreased 27.35% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $42000.0 in 2023, then soared by 178.57% to $117000.0 in 2024, then fell by 27.35% to $85000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $85000.0 in Q4 2025, $81000.0 in Q3 2025, and $79000.0 in Q2 2025.